-
Product Insights
Octapharma AG – Lingolsheim Alsatian Factory Extension – Grand-Est
Equip yourself with the essential tools needed to make informed and profitable decisions with our Octapharma AG - Lingolsheim Alsatian Factory Extension - Grand-Est report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
Octapharma AG/ PJSC Farmimeks – Ryazan Bio-pharmaceutical Plant – Rjazan
Equip yourself with the essential tools needed to make informed and profitable decisions with our Octapharma AG/ PJSC Farmimeks - Ryazan Bio-pharmaceutical Plant - Rjazan report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Company Profile
![]()
Octapharma AG – Company Profile
Octapharma AG (Octapharma) is a human protein product manufacturer that focuses on developing and producing medicines through human proteins from human plasma and cell lines. The company treats patients worldwide with products across immunotherapy, hematology, and critical care therapeutic areas. It sources plasma from company-owned plasma donation centers and other external sources. Octapharma owns plasma donation centers in the US and Germany and owns production facilities in Austria, Germany, France, Mexico, and Sweden. The company’s production plants carry out plasma...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INCA-033989 in Essential Thrombocythemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. INCA-033989 in Essential Thrombocythemia Drug Details: INCA-033989 is under development for the treatment of myelofibrosis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MOS-118 in Obstructive Sleep Apnea
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MOS-118 in Obstructive Sleep Apnea Drug Details: MOS-118 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LB-1908 in Esophageal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.LB-1908 in Esophageal CancerDrug Details:LB-1908 (LCAR-C18S) is under development for the treatment of relapsed or refractory...
-
Sector Analysis
Primary Immune Deficiency (PID) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Primary Immune Deficiency (PID) Marketed and Pipeline Drugs Overview PIDs, also known as inborn errors of immunity (IEI), are a group of more than 400 rare, chronic conditions. In this part of the body’s immune system is either missing or does not function correctly. Any component of the immune system—cells, proteins (immunoglobulins), enzymes involved in immune regulation—may be at defect causing PID. These conditions are caused by hereditary genetic defects and can affect anyone, regardless of age, gender, or ethnicity....
-
Company Insights
![]()
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Danburstotug in T-Cell Lymphomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Danburstotug in T-Cell Lymphomas Drug Details: STIA-1015 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Octanorm in Primary Immune Deficiency (PID)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Octanorm in Primary Immune Deficiency (PID) Drug Details: Immunoglobulin G (Human) (Octonorm) contains mainly normal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pemigatinib in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pemigatinib in Endometrial Cancer Drug Details: Pemigatinib (Pemazyre) is acts as an anti neoplastic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MK-4830 in Metastatic Breast Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MK-4830 in Metastatic Breast Cancer Drug Details: MK-4830 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MK-4830 in Colorectal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MK-4830 in Colorectal Cancer Drug Details: MK-4830 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Refractory Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Immune Globulin (Human) in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details: Human normal immunoglobulin (Octagam, ...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Immune Globulin (Human) in Chronic Lymphocytic Leukemia (CLL) Drug Details: Human normal immunoglobulin (Octagam, Gamten,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Relapsed Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Immune Globulin (Human) in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details: Human normal immunoglobulin (Octagam, ...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Rhabdomyosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Rhabdomyosarcoma Drug Details: Tazemetostat hydrobromide (Tazverik) is an anti-neoplastic agent. It is...
-
Sector Analysis
von Willebrand Disease (vWD) Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2032
The prevalence of vWD is increasing at a steady rate, in line with population growth in the 3MM, at an AGR of 0.61%. Currently, the treatment regimen for vWD in the 3MM is mostly limited to DDAVP and coagulation factor VIII + vWF complex. There are several unmet needs in this space, including the need for better diagnostic tools for vWD and improved therapies for severe vWD. The vWD late-stage R&D pipeline is focused on developing vWF recombinant for pediatric...
-
Product Insights
Von Willebrand Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Von Willebrand Disease (vWD) Clinical Trials Market Report Overview The Von Willebrand Disease (vWD) clinical trial market research report provides an overview of the Von Willebrand Disease (vWD) Clinical trials scenario. This report provides top-line data relating to the clinical trials on Von Willebrand Disease (vWD) and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Product Insights
Hemophilia A Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Hemophilia A (Factor VIII Deficiency) Clinical Trials Market Report Overview The Hemophilia A (Factor VIII Deficiency) clinical trial market research report provides an overview of the Hemophilia A clinical trials scenario. The report provides top-line data relating to the clinical trials on Hemophilia A. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.